The prevalence of low levels of high-density lipoprotein cholesterol among patients treated with lipid-lowering drugs

British Journal of Cardiology

Volumn 11, Issue 1, 2004, Pages 50-55

  Devroey, Dirk ^a   Velkeniers, Brigitte ^a,b   Betz, Willem ^a   Kartounian, Jan ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Cholesterol; Fibrate; Lipids; Lipoproteins; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PATIENT CARE; PREVALENCE; REIMBURSEMENT; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 1342267012     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. Am J Med 1951;11:480-5.
3. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.
4. Downs GR, Clearfield M, Weiss S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS (Air Force/Texas Coronary Atherosclerosis Study). JAMA 1998;279:1615-22.
5. Herd JA, Ballantyne CM, Farmer JA et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study, LCAS). Am J Cardiol 1997;80:278-86.
6. Frick MH, Syvanne M, Nieminen MS et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43.
7. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18.
8. Frick MH, Elu O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
9. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-07.
10. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
12. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. JAMA 1989;262:3154-60.
13. Devroey D, Betz W, Coigniez P, Lauwers R, Velkeniers B. A 'bad responder' to statins. Cardiology 2002;97:230-2.
14. Devroey D, Velkeniers B, Duquet W, Betz W. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta Cardiol 2003;58:179-84.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
16. Xhignesse M, Laplante P, Grant AM et al. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: are we doing enough? Can J Cardiol 1999;15:185-9.
17. Stagmo M, Westin L, Carlsson R, Israelsson B. Long-term effects on cholesterol levels and the utilisation of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease. J Cardiovasc Risk 2001;8:243-8.
18. Svilaas A, Thoresen M, Kristoffersen JE, Hjartaaker J, Westheim A. How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. Scand J Prim Health Care 2000;18:232-6.
19. De Henauw S, De Bacquer D, de Smet P, Kornitzer M, De Backer G. Trends and regional differences in coronary risk factors in two areas in Belgium: final results from the MONICA Ghent-Charleroi Study. J Cardiovasc Risk 2000;7:347-57.
20. Muls E, De Backer G, De Bacquer D, Brohet C, Heller F. LIPI-WATCH, a Belgian/Luxemburg survey on achievements of European Atherosclerosis Society Lipid goals. Clin Drug Invest 2000;19:219-29.
21. Muls E, De Backer G, Brohet C, Heller F. The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta Cardiol 2001;56:109-14.
22. Vanuzzo D, Pilotto L, Ambrosio GB et al. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events. Atherosclerosis 2000;153:505-17.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Full report available at www.nhlbi.nih.gov/guidelines/cholesterol/atp3℘t.htm
24. Maitland-van der Zee AH, Klungel OH, Stricker BH et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213-22.
25. O'Neill FH, Patel DD, Knight BL et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001;21:832-7.
26. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.